CTU: A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination with an Immune Checkpoint Inhibitor in Patients with Advanced Solid Tumors

  • Park, John (Primary Chief Investigator)
  • Chapman, Nicola (Clinical Trial Unit Staff)
  • Contacos, Christine (Clinical Trial Unit Staff)
  • TAIDI, Gina (Clinical Trial Unit Staff)
  • Chester, Catherine (Clinical Trial Unit Staff)

Project: Research

Project Details

Short titleMDNA11-01
AcronymABILITY
StatusActive
Effective start/end date25/07/23 → 26/04/28